SGLT2 Inhibition in Heart Failure: New Updates
Published: 08 February 2023
15m 19sPart 5 Panel Discussion
12m 35sPart 10 Panel Discussion
This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.
Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
- To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
- To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
- To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
- To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
- To assess the merit of ejection fraction in heart failure care
- Primary Care Physicians
- Diabetes Educators
More from this programme
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?
SGLT2 Inhibition in the Elderly and Frail Patients
Gender Differences in Outcomes With SGLT2 Inhibitors
Efficacy and Safety of SGLT2 Inhibitors in Black Patients
SGLT2 Inhibition in Patients With Improved EF
SGLT2 Inhibition With MRAs and ARNis
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?
Does EF Still Matter in HF Management?
John JV McMurray
Professor of Cardiology
Prof John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. A graduate of Manchester University, Prof McMurray completed postgraduate research at the University of Dundee.
Prof McMurray is a Fellow of the European Society of Cardiology (ESC), American College of Cardiology and American Heart Association as well as the medical Royal Colleges in Edinburgh and Glasgow and the Royal Society of Edinburgh and UK Academy of Medical Sciences.